DCAF13 and breast carcinoma: We report that doxorubicin, a widely used chemotherapy drug, increases DCAF13 expression in breast cancer cells, leading to enhanced cancer cell migration and invasion, suggesting that doxorubicin may increase the risk of metastasis of drug‐resistant breast cancer cells, and future therapeutics targeting DCAF13 may help reduce the risk.